Portfolio

	About us	R&D Projects	Media centre	People	Contact
Products Anergis aims at developing a number of COP based specific products against allergies with the highest medical need.	Anergis possesses a unique know-how and an exclusive license to the technology of Contiguous Overlapping Peptides (“COPs”) developed jointly by the University of Lausanne, Switzerland (UNIL), the Federal Institute of Technology (EPFL) and the Centre Hospitalier Universitaire Vaudois (CHUV). The technology of COPs allows the identification and development of uniquely profiled proprietary products for ultra-fast and safe desensitization. COPs are fragments of a specific allergen which have been selected to: present all T cell epitopes of the original allergen and have lost their ability to cross-react with IgE. With these properties, COP products are recognized by T cells but do not bind to IgEs and therefore do not elicit an immediate allergic response. COP products can therefore be administered at much higher doses than classical extracts or than the entire allergen. In the past years, Anergis has demonstrated: Successful definition of new COPs for two types of allergens with the desired pharmacological profile, namely: AllerB based on the bee venom allergen PLA2 AllerT based on the birch pollen allergen Bet v 1 Adequate immunogenicity in vitro and safety in rodents with both AllerB and AllerT No immediate hypersensitivity, as judged by skin reaction to AllerB and AllerT in patients allergic to bee venom and birch pollen respectively (skin prick tests). Safe administration of high doses of AllerB and AllerT in human within few days, equivalent to about ten times the dose usually reached after months of progressive dose increase in classical desensitization protocols. Cumulated dose reached in 6-10 weeks compared to 3-5 years for traditional SIT, achieved with both AllerB and AllerT in two independent placebo-controlled, randomized, double-blind clinical trials in allergic patients. Marked increase in specific serum IgG4, an immunological marker of tolerance, in allergic patients treated with COPs. Development Portfolio Anergis continues the development of its lead product AllerT against birch pollen allergies with the highest priority. In 2009, Anergis will initiate a second program targeting another well-defined respiratory allergy with high unmet medical need. Anergis is targeting the first food allergy indication, namely peanut allergies. The COP technology provides a unique opportunity of treating food allergies because of the lack of IgE cross-reactivity combined with the potential to desensitize patients against food allergens. Patients with food allergies currently only have the option of allergen avoidance as no therapeutic treatment is available to manage their allergies.

Products

Anergis aims at developing a number of COP based specific products against allergies with the highest medical need.

Molecular model

Anergis possesses a unique know-how and an exclusive license to the technology of Contiguous Overlapping Peptides (“COPs”) developed jointly by the University of Lausanne, Switzerland (UNIL), the Federal Institute of Technology (EPFL) and the Centre Hospitalier Universitaire Vaudois (CHUV).

The technology of COPs allows the identification and development of uniquely profiled proprietary products for ultra-fast and safe desensitization.

COPs are fragments of a specific allergen which have been selected to:

present all T cell epitopes of the original allergen and
have lost their ability to cross-react with IgE.

With these properties, COP products are recognized by T cells but do not bind to IgEs and therefore do not elicit an immediate allergic response. COP products can therefore be administered at much higher doses than classical extracts or than the entire allergen.

In the past years, Anergis has demonstrated:

Successful definition of new COPs for two types of allergens with the desired pharmacological profile, namely:

AllerB based on the bee venom allergen PLA2
AllerT based on the birch pollen allergen Bet v 1

Adequate immunogenicity in vitro and safety in rodents with both AllerB and AllerT
No immediate hypersensitivity, as judged by skin reaction to AllerB and AllerT in patients allergic to bee venom and birch pollen respectively (skin prick tests).
Safe administration of high doses of AllerB and AllerT in human within few days, equivalent to about ten times the dose usually reached after months of progressive dose increase in classical desensitization protocols.
Cumulated dose reached in 6-10 weeks compared to 3-5 years for traditional SIT, achieved with both AllerB and AllerT in two independent placebo-controlled, randomized, double-blind clinical trials in allergic patients.
Marked increase in specific serum IgG4, an immunological marker of tolerance, in allergic patients treated with COPs.

Development Portfolio

Anergis continues the development of its lead product AllerT against birch pollen
allergies with the highest priority.

In 2009, Anergis will initiate a second program targeting another well-defined respiratory allergy with high unmet medical need.

Anergis is targeting the first food allergy indication, namely peanut allergies. The COP technology provides a unique opportunity of treating food allergies because of the lack of IgE cross-reactivity combined with the potential to desensitize patients against food allergens. Patients with food allergies currently only have the option of allergen avoidance as no therapeutic treatment is available to manage their allergies.